180 related articles for article (PubMed ID: 34265505)
1. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
3. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
[TBL] [Abstract][Full Text] [Related]
4. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
5. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
[TBL] [Abstract][Full Text] [Related]
6. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
[TBL] [Abstract][Full Text] [Related]
7. Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.
Mignot F; Loirat D; Dureau S; Bataillon G; Caly M; Vincent-Salomon A; Berger F; Fourquet A; Pierga JY; Kirova YM; Bidard FC
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):389-396. PubMed ID: 30291993
[TBL] [Abstract][Full Text] [Related]
8. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
10. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.
Molloy TJ; Bosma AJ; Baumbusch LO; Synnestvedt M; Borgen E; Russnes HG; Schlichting E; van't Veer LJ; Naume B
Breast Cancer Res; 2011 Jun; 13(3):R61. PubMed ID: 21672237
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
[TBL] [Abstract][Full Text] [Related]
13. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
[TBL] [Abstract][Full Text] [Related]
14. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
[TBL] [Abstract][Full Text] [Related]
15. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
[TBL] [Abstract][Full Text] [Related]
16. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
[TBL] [Abstract][Full Text] [Related]
17. Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score.
Hartkopf AD; Wallwiener M; Kommoss S; Taran FA; Brucker SY
Breast Cancer Res Treat; 2016 Feb; 156(1):91-5. PubMed ID: 26911294
[TBL] [Abstract][Full Text] [Related]
18. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
[TBL] [Abstract][Full Text] [Related]
19. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
[TBL] [Abstract][Full Text] [Related]
20. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
